SCHEMBL443893

SCHEMBL443893

CC(=O)c1c[c]ccc1Cl

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 1/20 0.35
CES1 P23141 1/20 0.35
ALDH1A1 P00352 5/20 0.34
GABRA1 P14867 3/20 0.33
GABRG2 P18507 3/20 0.33
GABRB3 P28472 3/20 0.33
GABRB2 P47870 2/20 0.33
HPGD P15428 2/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
KMT2A Q03164 1/20 0.33
POLB P06746 2/20 0.32
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 1/20 0.32
TP53 P04637 1/20 0.32
CA12 O43570 1/20 0.31
CA9 Q16790 1/20 0.31
MAOB P27338 1/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL441463 0.83 MAPK1 (0.33) CES2CES1ALDH1A1SMN1; SMN2KMT2A
SCHEMBL443557 0.81 ALDH1A1 (0.50) CES2CES1ALDH1A1HPGDSMN1; SMN2
SCHEMBL2092525 0.80 ALDH1A1 (0.35) CES2CES1ALDH1A1HPGDSMN1; SMN2
SCHEMBL4806709 0.79 KMT2A (0.41) CES2CES1ALDH1A1GABRA1GABRG2
SCHEMBL6235866 0.79 CASP3 (0.31)
SCHEMBL4323616 0.79 ALDH1A1 (0.50) CES2CES1ALDH1A1HPGDSMN1; SMN2
SCHEMBL18547962 0.79 SMN1; SMN2 (0.43) ALDH1A1HPGDSMN1; SMN2KMT2APOLB
SCHEMBL5465624 0.79 ABL1 (0.42) ALDH1A1SMN1; SMN2KMT2APOLBCA12
SCHEMBL1450340 0.78 SMN1; SMN2 (0.37) ALDH1A1HPGDSMN1; SMN2KMT2APOLB
SCHEMBL7858414 0.78 CA12 (0.42) ALDH1A1HPGDKMT2APOLBCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102264700-B Can be used as the dihydropyridine keto-amide of the medicine for the treatment of autoimmunization and inflammatory diseases HOFFMAN-LA ROCHE LTD. (CH) 2015-08-19 CN disclosed
CN-102264702-B Dihydropyridinone amides as P2X7 modulators HOFFMANN LA ROCHE 2015-03-25 CN disclosed
US-8735387-B2 Oxazolopyrimidines as Edg-1 receptor agonists SANOFI (FR) 2014-05-27 US disclosed
EP-2684871-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives F. Hoffmann-La Roche AG (CH) 2014-01-15 EP disclosed
US-8513425-B2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC (US) 2013-08-20 US disclosed
EP-2354124-B1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE (CH) 2013-02-13 EP disclosed
CN-101563319-B Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE 2012-09-05 CN disclosed
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF IYER PRAVIN (US) 2012-03-15 US disclosed
US-8084623-B2 heterocyclic ketones such as (3-Benzyl-pyrrolidin-3-yl)-(1H-indol-5-yl)-methanone, used as antidepressants or anxiolytic agents ROCHE PALO ALTO LLC (US) 2011-12-27 US disclosed
EP-2354124-A2 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives F. Hoffmann-La Roche AG (CH) 2011-08-10 EP disclosed
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2011-08-04 US disclosed
CN-101563319-A Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives HOFFMANN LA ROCHE (CH) 2009-10-21 CN disclosed
EP-2102157-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. Hoffmann-Roche AG (CH) 2009-09-23 EP disclosed
WO-2008074703-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-26 WO disclosed
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof ROCHE PALO ALTO LLC 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS EDNRA, OXGR1, EDF1 CES2 4365/4885CES1 2454/4885ALDH1A1 1007/4885
US-20120065225-A1 HETEROARYL PYRROLIDINYL AND PIPERIDINYL KETONE DERIVATIVES AND USES THEREOF CNKSR1, RB1, AR CES2 3504/4885CES1 2883/4885ALDH1A1 447/4885
US-20080146607-A1 Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives and uses thereof CNKSR1, RB1, AR CES2 3504/4885CES1 2883/4885ALDH1A1 447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.